个人中心 - 老虎社区

3088b857

IP属地：未知

帖子 · 19帖子 · 19
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 3088b8573088b857
  ·2021-07-13
  Like
  非常抱歉，此主贴已删除
  1,756 评论
  1
  分享
  举报
- 3088b8573088b857
  ·2021-06-22
  Oh
  非常抱歉，此主贴已删除
  1,588 评论
  1
  分享
  举报
- 3088b8573088b857
  ·2021-06-21
  Nice
  Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>
  (June 21) Orphazyme rose more than 6% in premarket trading. What happened Shares of Orphazyme, a c
  Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>
  1,755 评论
  1
  分享
  举报
- 3088b8573088b857
  ·2021-06-21
  Ok
  非常抱歉，此主贴已删除
  1,501 评论
  3
  分享
  举报
- 3088b8573088b857
  ·2021-06-19
  Like
  非常抱歉，此主贴已删除
  2,863 评论
  1
  分享
  举报
- 3088b8573088b857
  ·2021-06-18
  [Doubt]
  非常抱歉，此主贴已删除
  1,924 评论
  1
  分享
  举报
- 3088b8573088b857
  ·2021-06-18
  [Lovely]
  非常抱歉，此主贴已删除
  2,270 评论
  点赞
  分享
  举报
- 3088b8573088b857
  ·2021-06-18
  Tell me your opinion about this news...
  非常抱歉，此主贴已删除
  1,598 评论
  点赞
  分享
  举报
- 3088b8573088b857
  ·2021-06-18
  [Strong]
  非常抱歉，此主贴已删除
  2,156 评论
  点赞
  分享
  举报
- 3088b8573088b857
  ·2021-06-18
  [Smile] [Smile]
  Ford Lifts Profit Guidance While F-150 Lightning, New Vehicles See Strong Demand<blockquote>福特上调利润指引，F-150 Lightning和新车需求强劲</blockquote>
  Ford joined GM with upbeat earnings guidance and sees strong reservations for critical new vehicles including its first electric truck.
  Ford Lifts Profit Guidance While F-150 Lightning, New Vehicles See Strong Demand<blockquote>福特上调利润指引，F-150 Lightning和新车需求强劲</blockquote>
  1,577 评论
  点赞
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3566691395182663","uuid":"3566691395182663","gmtCreate":1603597371989,"gmtModify":1623853851282,"name":"3088b857","pinyin":"charlotte26","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":19,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":"60.86%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":142822709,"gmtCreate":1626141928501,"gmtModify":1633929709721,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/142822709","repostId":"1175534160","repostType":4,"isVote":1,"tweetType":1,"viewCount":1756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120449218,"gmtCreate":1624334394634,"gmtModify":1634007615116,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120449218","repostId":"1191349655","repostType":4,"isVote":1,"tweetType":1,"viewCount":1588,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167677108,"gmtCreate":1624268018504,"gmtModify":1634008661767,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167677108","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://www.laohu8.com/m/news/1184501396?lang=zh_CN&edition=full","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p><p><blockquote>（6月21日）Orphazyme盘前交易涨超6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p><p><blockquote>本公司之股份<b>Orphazyme</b>一家处于临床阶段的生物制药公司在食品和药物管理局(FDA)拒绝批准该公司主要候选药物的申请后受到了打击。投资者现在不确定该生物技术公司何时可以获得批准的产品出售，截至中午12点12分，该股股价下跌44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA去年9月开始审查Orphazyme的主要候选药物arimoclomol的申请，作为一种罕见但危及生命的疾病（称为C型奈曼-皮克病(NPC)）的潜在治疗方法。本月早些时候，由于预期绿灯从未到来，Orphazymes的股价飙升超过200%。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有对arimoclomol做出批准决定，而是以完整回复信(CRL)的形式要求提供更多信息。这让许多刚接触复杂的药物开发领域并预计会出现大规模轧空的投资者感到震惊。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者对Orphazyme做空，因为其主要候选药物未能达到支持该申请的关键研究的主要终点。Arimoclomol也未能改善患者在FDA特别要求的次要终点上的评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了让FDA满意，该公司很可能必须进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去对罕见疾病的治疗更加宽容，但在产生一些令人信服的临床试验结果之前，arimoclomol可能不会向前推进。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，但这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算超过5亿美元。非理性的预期可能会使其居高不下，但对于Orphazyme的任何临床阶段生物技术来说，这都太高了。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-21 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(June 21)&nbsp;Orphazyme rose more than 6% in premarket trading.&nbsp;</p><p><blockquote>（6月21日）Orphazyme盘前交易涨超6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last&nbsp;Friday.</p><p><blockquote>本公司之股份<b>Orphazyme</b>一家处于临床阶段的生物制药公司在食品和药物管理局(FDA)拒绝批准该公司主要候选药物的申请后受到了打击。投资者现在不确定该生物技术公司何时可以获得批准的产品出售，截至中午12点12分，该股股价下跌44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA去年9月开始审查Orphazyme的主要候选药物arimoclomol的申请，作为一种罕见但危及生命的疾病（称为C型奈曼-皮克病(NPC)）的潜在治疗方法。本月早些时候，由于预期绿灯从未到来，Orphazymes的股价飙升超过200%。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有对arimoclomol做出批准决定，而是以完整回复信(CRL)的形式要求提供更多信息。这让许多刚接触复杂的药物开发领域并预计会出现大规模轧空的投资者感到震惊。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者对Orphazyme做空，因为其主要候选药物未能达到支持该申请的关键研究的主要终点。Arimoclomol也未能改善患者在FDA特别要求的次要终点上的评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了让FDA满意，该公司很可能必须进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去对罕见疾病的治疗更加宽容，但在产生一些令人信服的临床试验结果之前，arimoclomol可能不会向前推进。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，但这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算超过5亿美元。非理性的预期可能会使其居高不下，但对于Orphazyme的任何临床阶段生物技术来说，这都太高了。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":1755,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167674785,"gmtCreate":1624267997047,"gmtModify":1634008661990,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167674785","repostId":"1154249454","repostType":4,"isVote":1,"tweetType":1,"viewCount":1501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165091616,"gmtCreate":1624079232035,"gmtModify":1634010936496,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165091616","repostId":"2144034771","repostType":4,"isVote":1,"tweetType":1,"viewCount":2863,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166480199,"gmtCreate":1624022514011,"gmtModify":1634023995857,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"[Doubt]&nbsp;","listText":"[Doubt]&nbsp;","text":"[Doubt]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166480199","repostId":"1164089282","repostType":4,"isVote":1,"tweetType":1,"viewCount":1924,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166417840,"gmtCreate":1624022494880,"gmtModify":1634023996561,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"[Lovely]&nbsp;","listText":"[Lovely]&nbsp;","text":"[Lovely]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166417840","repostId":"1181667218","repostType":4,"isVote":1,"tweetType":1,"viewCount":2270,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168462546,"gmtCreate":1623981233985,"gmtModify":1634024788926,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168462546","repostId":"2144374909","repostType":4,"isVote":1,"tweetType":1,"viewCount":1598,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168462335,"gmtCreate":1623981219127,"gmtModify":1634024789411,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"[Strong]&nbsp;","listText":"[Strong]&nbsp;","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168462335","repostId":"2144490227","repostType":4,"isVote":1,"tweetType":1,"viewCount":2156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168528788,"gmtCreate":1623979040844,"gmtModify":1634024864907,"author":{"id":"3566691395182663","authorId":"3566691395182663","name":"3088b857","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3566691395182663","idStr":"3566691395182663"},"themes":[],"htmlText":"[Smile]&nbsp;[Smile]&nbsp;","listText":"[Smile]&nbsp;[Smile]&nbsp;","text":"[Smile] [Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168528788","repostId":"2144742524","repostType":4,"repost":{"id":"2144742524","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1623942517,"share":"https://www.laohu8.com/m/news/2144742524?lang=zh_CN&edition=full","pubTime":"2021-06-17 23:08","market":"us","language":"en","title":"Ford Lifts Profit Guidance While F-150 Lightning, New Vehicles See Strong Demand<blockquote>福特上调利润指引，F-150 Lightning和新车需求强劲</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2144742524","media":"Investors","summary":"Ford joined GM with upbeat earnings guidance and sees strong reservations for critical new vehicles including its first electric truck.","content":"<p><b>Ford</b> joined <b>General Motors</b> with upbeat earnings guidance and sees strong reservations for critical new vehicles including its first electric truck. Ford stock rose.</p><p><blockquote><b>福特</b>加入<b>通用汽车</b>凭借乐观的盈利指引，并看到包括首款电动卡车在内的关键新车的强劲预订。福特股价上涨。</blockquote></p><p> The No. 2 U.S. auto giant said Thursday that it expects adjusted pretax earnings for the second quarter to surpass its own expectations and be \"significantly better\" than a year ago.</p><p><blockquote>这家美国第二大汽车巨头周四表示，预计第二季度调整后税前收益将超过自己的预期，并“明显好于”一年前。</blockquote></p><p> That's despite the semiconductor shortage, which Ford said April 28 would halve its planned Q2 production and reduce full-year adjusted EBIT to $5.5 billion-$6.5 billion.</p><p><blockquote>尽管半导体短缺，福特4月28日表示，将把第二季度计划产量减半，并将全年调整后息税前利润降至55亿至65亿美元。</blockquote></p><p> Ford did not offer specific Q2 guidance on April 28 or Thursday. It will report for Q2 and offer outlook for the rest of the year July 28.</p><p><blockquote>福特在4月28日或周四没有提供具体的第二季度指引。它将于7月28日发布第二季度报告并提供今年剩余时间的展望。</blockquote></p><p> On Wednesday, GM forecast adjusted earnings before taxes of $8.5 billion-$9.5 billion in the first half of 2021, up from an earlier view for $5.5 billion, due to strong demand for its SUVs and trucks. GM remains cautious for the full year.</p><p><blockquote>周三，通用汽车预测2021年上半年调整后税前利润为85亿至95亿美元，高于此前预期的55亿美元，原因是对其SUV和卡车的强劲需求。通用汽车对全年仍保持谨慎态度。</blockquote></p><p> Also Thursday, Ford touted 100,000 reservations for the F-150 Lightning, its first all-electric pickup truck and <b>Tesla</b> Cybertruck rival. That's up from 20,000 reported May 20 after a launch event, and 70,000 on May 26.</p><p><blockquote>同样在周四，福特宣布F-150 Lightning的预订量为10万辆，这是其首款全电动皮卡和<b>特斯拉</b>赛博卡车的竞争对手。这高于5月20日发布活动后报道的20,000人和5月26日报道的70,000人。</blockquote></p><p> Meanwhile, its new compact Maverick truck has 36,000 reservations, just a week after unveiling. Ford also reported 20,000 reservations for the all-electric E-Transit commercial van and 190,000 for the new, full-size Bronco SUV.</p><p><blockquote>与此同时，其新款紧凑型Maverick卡车在推出仅一周后就获得了36,000份预订。福特还报告称，全电动E-Transit商用货车的预订量为20,000辆，新款全尺寸Bronco SUV的预订量为190,000辆。</blockquote></p><p> CEO Jim Farley will further address Q2 financial guidance at a Deutsche Bank auto industry conference Thursday afternoon.</p><p><blockquote>首席执行官吉姆·法利(Jim Farley)将在周四下午的德意志银行汽车行业会议上进一步阐述第二季度财务指引。</blockquote></p><p> <h2>Ford Stock</h2> Shares rose 1.3% to 15.22 in Thursday's stock market. Ford stock, on the IBD Leaderboard, is extended from a cup-without-handle 13.72 buy point, cleared late May on its bold EV shift. GM stock eased 1% to 61.07 as it eyes a 63.54 cup-shaped buy point.</p><p><blockquote><h2>福特股票</h2>周四股市上涨1.3%，至15.22点。IBD排行榜上的福特股票从5月底大胆转向电动汽车而获得的13.72买入点延伸。通用汽车股价下跌1%，至61.07点，关注63.54点的杯形买入点。</blockquote></p><p> On Wednesday, GM announced it will invest $35 billion to develop electric vehicles (EVs) and autonomous vehicles (AVs) through 2025. That's a 30% increase from its most recent forecast for $27 billion set last November, and a 75% increase from an initial forecast of $20 billion set in March 2020.</p><p><blockquote>周三，通用汽车宣布将在2025年前投资350亿美元开发电动汽车（EV）和自动驾驶汽车（AV）。这比去年11月设定的270亿美元的最新预测增长了30%，比2020年3月设定的200亿美元的初步预测增长了75%。</blockquote></p><p> By comparison, Ford in May announced $30 billion on EV- AV spending through 2025, up from a prior view for $22 billion.</p><p><blockquote>相比之下，福特5月份宣布，到2025年，EV-AV支出将达到300亿美元，高于之前预期的220亿美元。</blockquote></p><p> But Ford's investments include years prior to 2020, while GM's spending is for 2020 through 2025.</p><p><blockquote>但福特的投资包括2020年之前的几年，而通用汽车的支出是2020年至2025年。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford Lifts Profit Guidance While F-150 Lightning, New Vehicles See Strong Demand<blockquote>福特上调利润指引，F-150 Lightning和新车需求强劲</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord Lifts Profit Guidance While F-150 Lightning, New Vehicles See Strong Demand<blockquote>福特上调利润指引，F-150 Lightning和新车需求强劲</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time smaller\">2021-06-17 23:08</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Ford</b> joined <b>General Motors</b> with upbeat earnings guidance and sees strong reservations for critical new vehicles including its first electric truck. Ford stock rose.</p><p><blockquote><b>福特</b>加入<b>通用汽车</b>凭借乐观的盈利指引，并看到包括首款电动卡车在内的关键新车的强劲预订。福特股价上涨。</blockquote></p><p> The No. 2 U.S. auto giant said Thursday that it expects adjusted pretax earnings for the second quarter to surpass its own expectations and be \"significantly better\" than a year ago.</p><p><blockquote>这家美国第二大汽车巨头周四表示，预计第二季度调整后税前收益将超过自己的预期，并“明显好于”一年前。</blockquote></p><p> That's despite the semiconductor shortage, which Ford said April 28 would halve its planned Q2 production and reduce full-year adjusted EBIT to $5.5 billion-$6.5 billion.</p><p><blockquote>尽管半导体短缺，福特4月28日表示，将把第二季度计划产量减半，并将全年调整后息税前利润降至55亿至65亿美元。</blockquote></p><p> Ford did not offer specific Q2 guidance on April 28 or Thursday. It will report for Q2 and offer outlook for the rest of the year July 28.</p><p><blockquote>福特在4月28日或周四没有提供具体的第二季度指引。它将于7月28日发布第二季度报告并提供今年剩余时间的展望。</blockquote></p><p> On Wednesday, GM forecast adjusted earnings before taxes of $8.5 billion-$9.5 billion in the first half of 2021, up from an earlier view for $5.5 billion, due to strong demand for its SUVs and trucks. GM remains cautious for the full year.</p><p><blockquote>周三，通用汽车预测2021年上半年调整后税前利润为85亿至95亿美元，高于此前预期的55亿美元，原因是对其SUV和卡车的强劲需求。通用汽车对全年仍保持谨慎态度。</blockquote></p><p> Also Thursday, Ford touted 100,000 reservations for the F-150 Lightning, its first all-electric pickup truck and <b>Tesla</b> Cybertruck rival. That's up from 20,000 reported May 20 after a launch event, and 70,000 on May 26.</p><p><blockquote>同样在周四，福特宣布F-150 Lightning的预订量为10万辆，这是其首款全电动皮卡和<b>特斯拉</b>赛博卡车的竞争对手。这高于5月20日发布活动后报道的20,000人和5月26日报道的70,000人。</blockquote></p><p> Meanwhile, its new compact Maverick truck has 36,000 reservations, just a week after unveiling. Ford also reported 20,000 reservations for the all-electric E-Transit commercial van and 190,000 for the new, full-size Bronco SUV.</p><p><blockquote>与此同时，其新款紧凑型Maverick卡车在推出仅一周后就获得了36,000份预订。福特还报告称，全电动E-Transit商用货车的预订量为20,000辆，新款全尺寸Bronco SUV的预订量为190,000辆。</blockquote></p><p> CEO Jim Farley will further address Q2 financial guidance at a Deutsche Bank auto industry conference Thursday afternoon.</p><p><blockquote>首席执行官吉姆·法利(Jim Farley)将在周四下午的德意志银行汽车行业会议上进一步阐述第二季度财务指引。</blockquote></p><p> <h2>Ford Stock</h2> Shares rose 1.3% to 15.22 in Thursday's stock market. Ford stock, on the IBD Leaderboard, is extended from a cup-without-handle 13.72 buy point, cleared late May on its bold EV shift. GM stock eased 1% to 61.07 as it eyes a 63.54 cup-shaped buy point.</p><p><blockquote><h2>福特股票</h2>周四股市上涨1.3%，至15.22点。IBD排行榜上的福特股票从5月底大胆转向电动汽车而获得的13.72买入点延伸。通用汽车股价下跌1%，至61.07点，关注63.54点的杯形买入点。</blockquote></p><p> On Wednesday, GM announced it will invest $35 billion to develop electric vehicles (EVs) and autonomous vehicles (AVs) through 2025. That's a 30% increase from its most recent forecast for $27 billion set last November, and a 75% increase from an initial forecast of $20 billion set in March 2020.</p><p><blockquote>周三，通用汽车宣布将在2025年前投资350亿美元开发电动汽车（EV）和自动驾驶汽车（AV）。这比去年11月设定的270亿美元的最新预测增长了30%，比2020年3月设定的200亿美元的初步预测增长了75%。</blockquote></p><p> By comparison, Ford in May announced $30 billion on EV- AV spending through 2025, up from a prior view for $22 billion.</p><p><blockquote>相比之下，福特5月份宣布，到2025年，EV-AV支出将达到300亿美元，高于之前预期的220亿美元。</blockquote></p><p> But Ford's investments include years prior to 2020, while GM's spending is for 2020 through 2025.</p><p><blockquote>但福特的投资包括2020年之前的几年，而通用汽车的支出是2020年至2025年。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGD":"New Gold","F":"福特汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144742524","content_text":"Ford joined General Motors with upbeat earnings guidance and sees strong reservations for critical new vehicles including its first electric truck. Ford stock rose.\nThe No. 2 U.S. auto giant said Thursday that it expects adjusted pretax earnings for the second quarter to surpass its own expectations and be \"significantly better\" than a year ago.\nThat's despite the semiconductor shortage, which Ford said April 28 would halve its planned Q2 production and reduce full-year adjusted EBIT to $5.5 billion-$6.5 billion.\nFord did not offer specific Q2 guidance on April 28 or Thursday. It will report for Q2 and offer outlook for the rest of the year July 28.\nOn Wednesday, GM forecast adjusted earnings before taxes of $8.5 billion-$9.5 billion in the first half of 2021, up from an earlier view for $5.5 billion, due to strong demand for its SUVs and trucks. GM remains cautious for the full year.\nAlso Thursday, Ford touted 100,000 reservations for the F-150 Lightning, its first all-electric pickup truck and Tesla Cybertruck rival. That's up from 20,000 reported May 20 after a launch event, and 70,000 on May 26.\nMeanwhile, its new compact Maverick truck has 36,000 reservations, just a week after unveiling. Ford also reported 20,000 reservations for the all-electric E-Transit commercial van and 190,000 for the new, full-size Bronco SUV.\nCEO Jim Farley will further address Q2 financial guidance at a Deutsche Bank auto industry conference Thursday afternoon.\nFord Stock\nShares rose 1.3% to 15.22 in Thursday's stock market. Ford stock, on the IBD Leaderboard, is extended from a cup-without-handle 13.72 buy point, cleared late May on its bold EV shift. GM stock eased 1% to 61.07 as it eyes a 63.54 cup-shaped buy point.\nOn Wednesday, GM announced it will invest $35 billion to develop electric vehicles (EVs) and autonomous vehicles (AVs) through 2025. That's a 30% increase from its most recent forecast for $27 billion set last November, and a 75% increase from an initial forecast of $20 billion set in March 2020.\nBy comparison, Ford in May announced $30 billion on EV- AV spending through 2025, up from a prior view for $22 billion.\nBut Ford's investments include years prior to 2020, while GM's spending is for 2020 through 2025.","news_type":1,"symbols_score_info":{"GUID":0.9,"NGD":0.9,"F":0.9}},"isVote":1,"tweetType":1,"viewCount":1577,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":false}